- Report
- February 2021
- 360 Pages
United States
From €2316EUR$2,400USD£1,987GBP
- Report
- February 2019
- 105 Pages
Global
From €1245EUR$1,290USD£1,068GBP
- Report
- June 2019
- 14 Pages
Global
€9652EUR$10,000USD£8,279GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €483EUR$500USD£414GBP
- Report
- January 2019
- 35 Pages
Global
From €965EUR$1,000USD£828GBP
Sustiva (efavirenz) is an antiretroviral drug used in the treatment of HIV infection. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by blocking the action of the enzyme reverse transcriptase, which is needed for the virus to replicate. Sustiva is usually prescribed in combination with other antiretroviral drugs to treat HIV infection. It is also used to prevent HIV infection in people who are at high risk of contracting the virus.
Sustiva is a widely used drug in the infectious diseases market. It is used to treat HIV infection and is also used in combination with other antiretroviral drugs to treat other infections such as hepatitis B and C. It is also used to prevent HIV infection in people who are at high risk of contracting the virus.
Companies in the Sustiva market include Bristol-Myers Squibb, Merck, Gilead Sciences, and ViiV Healthcare. Show Less Read more
